title: Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
abstract: Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically associated with the t(11;14) chromosomal translocation, resulting in overexpression of cyclin D1. Although MCL is associated with clinical heterogeneity, outcomes are generally poor and no standard treatment has been established. However, the recent approval of ibrutinib provides a new therapeutic option. Moreover, recent clinical trials have provided new perspectives on the relative efficacy and safety of various approaches for both transplant-eligible and transplant-ineligible patients. Multiple novel strategies are being evaluated in the treatment of MCL, including both targeted agents and cellular immunotherapies. At the Lymphoma Research Foundation's 12th MCL Workshop, researchers gathered to discuss research findings, clinical trial results, and future directions related to MCL, its biology, and its treatment. This manuscript, which includes a summary of each presentation, aims to review recent findings in MCL research and highlight potential areas for future study.
authors.affiliation: a Department of Medicine, Washington University in Saint Louis , St. Louis , MO , USA.
authors.forename: Brad S
authors.initials: BS
authors.lastname: Kahl
authors.affiliation: b Department of Medicine, University of Munich-Grosshadern , Munich , Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Dreyling
authors.affiliation: c Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center , Chicago , IL , USA.
authors.forename: Leo I
authors.initials: LI
authors.lastname: Gordon
authors.affiliation: d Department of Medicine, Eberhard-Karls-University , Tuebingen , Germany.
authors.forename: Leticia
authors.initials: L
authors.lastname: Quintanilla-Martinez
authors.affiliation: e Department of Medicine, George Washington University , Washington DC , USA.
authors.forename: Eduardo M
authors.initials: EM
authors.lastname: Sotomayor
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis* / Q000628:therapy*; D016896:Treatment Outcome
keywords: Lymphoma and Hodgkin’s disease; clinical results; immunotherapy; marrow and stem cell transplantation; pharmacotherapeutics; tumor microenvironment